Skip to main content
ERAS logo

ERAS · Erasca, Inc.

Track ERAS — free
$13.61 -0.61 (-4.29%) At close · Nov 20
Market Cap
$4.78B
Shares
350.96M
Volume · Nov 20 11.07M Avg daily vol (3M) 5.23M

Price & Indicators

 

Key stats

Close
$13.61
Fri 20 Nov
Open
$13.13
Fri 20 Nov
Average volume, 30 days
5.7M
shares a session
Short interest
37.2M
10.6% of shares · 8.9 days to cover
Day range
$13.13$14.31
Open $13.13 Close $13.61
52-week closing range
$2.78$22.47
Close $13.61 39.4% under the high
Short volume, last session
55%
Last earnings
May 8, 2024
Latest filing
10-Q · Nov 12
Price history
Jul 2021 to Nov 2026

Up next

call held Mar 27, 2024

Latest documents

2026
Nov 20
Current report 8-K
ERAS-0015 shows 44% pancreatic cancer response rate in updated data

Erasca's ERAS-0015 showed a 44% confirmed objective response rate across 25 patients with KRAS G12X mutations. The Phase 3 trial in first-line pancreatic cancer is accelerated to the first half of 2027.

Other events
3 source passages
On November 20, 2026, Erasca, Inc. (the “Company”) announced updated U.S. Phase 1 monotherapy and initial combination data reinforcing the best-in-class potential of pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. 44% confirmed objective response rate (“ORR”) across all patients (N=25) with KRAS G12X mutations The Company is accelerating the planned initiation of a Phase 3 trial in first-line (“1L”) pancreatic cancer to the first half of 2027. Open the document at this passage
Nov 18
Investor event
32 milligram cohort guided to more than double patients

The CEO said the 32 milligram cohort had about seven patients in July and is guided to more than double that. He said 32 milligrams did seem like the most promising dose based on the July data. The CFO said a collaboration with BMS for NABLI metastat, a PRMT5 inhibitor, was announced the previous evening.

3 source passages
And while in July, there were only about seven patients, we are guiding to more than double that 32 milligrams did seem like the most promising dose we just announced yesterday evening a collaboration with BMS for NABLI metastat, their PRMT5 inhibitor Open the document at this passage
Nov 12
Current report 8-K
ERAS-0015 earns FDA Fast Track as cash reaches $948 million

Erasca reported that ERAS-0015 received FDA Fast Track Designation for metastatic pancreatic adenocarcinoma, while cash, cash equivalents, and marketable securities totaled $948 million as of September 30, 2026.

Financial results
2 source passages
ERAS-0015 granted FDA Fast Track Designation for metastatic pancreatic adenocarcinoma; advancing toward three potentially registration-enabling trials in pancreatic and lung cancers Cash, cash equivalents, and marketable securities of $948 million as of September 30, 2026 Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
ERAS-0015 delivered 62% and 75% response rates in NSCLC

ERAS-0015 showed preliminary Phase 1 monotherapy response rates of 62% (N=37) in 2L+ KRAS G12X NSCLC and 75% (N=16) in post-ICI/platinum KRAS G12X NSCLC at 16-32 mg QD.

Net loss $51.33M Diluted EPS -$0.15
Read from the MD&A section
3 source passages
On April 27, 2026, we announced positive preliminary Phase 1 dose escalation data for ERAS-0015 from our AURORAS-1 trial and the Joyo JYP0015M101 trial. At PADs of 16-32 mg QD, 62% uORR8wk (N=37) in second line or greater (2L+) KRAS G12X NSCLC, which exceeded comparator by 24 percentage points3,4 At PADs of 16-32 mg QD, 75% uORR8wk (N=16) in post-ICI/platinum (2/3L) KRAS G12X NSCLC, which exceeded comparator by 37 percentage points3,4 Open the document at this passage
Nov 10
Investor event
Three registration-enabling studies planned after $632 million raise

ERAS plans three registration-enabling studies after raising $632 million in July, with pancreatic phase three initiation in 2027 and lung phase three starts between the second half of 27 and first half of 28.

4 source passages
That does not include the $632 million that we subsequently raised in July. including initiating those three potential registration enabling studies, two in lung, one in PANQ. our guidance has been 2027 in terms of starting that, and we're on track for that. we've broadbanded the guidance for that first-line trial for phase three between second half of 27 and first half of 28. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$307.94M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-2.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$643.70M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+21.3%
Year over year · more shares
Price change (1Y)
+389.6%
Trailing year
Short interest
10.6%
Latest settlement · 8.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −11%
below
Price vs 50-day avg −8%
below
RSI (14) 43
neutral
MACD trend Negative
52-week position 55%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −5%
trailing
6-month return +1%
trailing
YTD return +266%
this year
Relative strength +10%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $15 › 200d $15 — 200d above 50d
Institutional flow Accumulating
+8% holders QoQ · +50 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.59% of shares out · ▲ +0.5% MoM · 8.9 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
279 holders — near 3-yr high, broad support
Squeeze score 77
high risk · 0–100
Fundamentals
Strong
EPS growth +36%
Y/Y
Free cash flow $-95.6M
Balance sheet $73.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 103%
annualized · 1-yr
Max drawdown −59%
past year
ATR 9.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−11% Bearish
Price vs 50-day avg
−8% Bearish
RSI (14)
43 Neutral
MACD trend
Negative Bearish
52-week position
55% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $15 › 200d $15 — 200d above 50d
Institutional flow Accumulating
+8% holders QoQ · +50 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.59% of shares out · ▲ +0.5% MoM · 8.9 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
279 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $14 · 55% Range high $22
vs 200-day avg -11% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Gross proceeds from upsized public offering $632.5M July 2026 —
Median relative dose intensity 100% Q2 2026 —
uORR8wk 57% Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ERAS
Erasca, Inc.
this stock
$4.78B +265.9% — — 10.6%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
279
% held
93.2%
Net QoQ
+46.9M sh
Top holder
Frazier Life Sciences Man…
Held Float
View
Held by Funds
Fund positions
257
View
Short & Settlement
Short Interest Rising
Shares short
37.2M
Days to cover
8.9d
Change
+193.2K sh
View
Short Volume
Short vol %
55%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
351
Value
$5.3K
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
44.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-124.5M
EPS diluted
$-0.44
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 20, 2026
This year
29

Erasca's ERAS-0015 showed a 44% confirmed objective response rate across 25 patients with KRAS G12X mutations. The Phase 3 trial in first-line pancreatic cancer is accelerated to the first half of 2027.

View
Proposed Sales
Value
$1.3M
Shares
80.0K
Filed
Apr 1, 2026
View
Exempt Offerings
Offering
$374.5M
Filed
Apr 30, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 20, 2026
View
Investor Relations
Latest news
Erasca Reports Broad and Robust P…
Published
Nov 20, 2026
View

Performance

5D 20D 120D MTD YTD
ERAS -13.1% -5.4% +1.0% -5.2% +265.9%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -4.5% +3.8% +10.1% +3.6% +264.7%
Key facts CIK 1761918 CUSIP 29479A108 13F (30d) 282 filings 260 filers Visit website Investor relations